Daiichi Sankyo therapeutic area oncology development head Mark Rutstein said: “Following the positive results in the endometrial cancer cohort of DESTINY-PanTumor02, which contributed to a ...

The first patient has been dosed in the DESTINY-Endometrial01 phase 3 trial evaluating ENHERTU ® (trastuzumab deruxtecan) in combination with rilvegostomig or pembrolizumab versus platinum-based ...

DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer ...

DESTINY-Endometrial01 is a global, multicenter, randomized, open-label phase 3 trial evaluating the efficacy and safety of ENHERTU (5.4 mg/kg) in combination with rilvegostomig or pembrolizumab versus ...

Even though it is a handheld console and therefore runs on weaker hardware compared to its contemporaries, a gap that felt even wider when it launched in 2004, the Nintendo DS ranked among the ...

Enhertu (6.4mg/kg) is approved in more than 70 countries worldwide for the treatment of adult patients with locally advanced or metastatic HER2-positive (IHC 3+ or 2+/ISH+) gastric or gastroesophageal ...

The French Stellantis subsidiary DS unveiled the new DS N°4 in mid-May and has now also announced the prices for the French market. The battery-electric offshoot DS N°4 E-Tense starts in the Pallas ...

Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, Medicare patients.

Due to a technical issue, this story was not posted in its entirety. It has been updated to include the missing portion. NEW YORK – A dual HER2-targeted combination of the antibody-drug conjugate ...

Presented at ASCO 2025, new data from the DESTINY-Breast09 trial showed that Enhertu plus pertuzumab cut the risk of disease progression or death by 44% compared to taxane, trastuzumab, and pertuzumab ...

AstraZeneca and Daiichi Sankyo’s ENHERTU plus pertuzumab showed a median progression-free survival greater than three years. First trial in more than a decade to demonstrate an improvement in outcomes ...